SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

AstraZeneca Pharma India informs about closure of trading window

15 Dec 2023 Evaluate

In accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, read with AstraZeneca Pharma India - Code of Conduct for Prevention of Insider Trading, AstraZeneca Pharma India has informed that the Trading Window for dealing in the Equity Shares of the Company will be closed from December 16, 2023 and the same shall reopen after 48 hours from the declaration of Unaudited Financial Results of the Company for the quarter ending December 31, 2023.

The above information is a part of company’s filings submitted to BSE.

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×